Australia markets closed

Microba Life Sciences Limited (MAP.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.19500.0000 (0.00%)
At close: 12:16PM AEST
Full screen
Previous close0.1950
Bid0.1950 x N/A
Ask0.2000 x N/A
Day's range0.1950 - 0.1970
52-week range0.1500 - 0.4247
Avg. volume476,275
Market cap87.331M
Beta (5Y monthly)2.76
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update

    ColoAlert® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and MAINZ, Germany, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the results of the first six months and second quarter ending June 30, 2023 and provi

  • Business Wire

    First Distribution Agreement Executed with Sonic Healthcare

    BRISBANE, Australia, July 05, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia (Distribution Agreement).

  • Business Wire

    Microba Commences Phase I Clinical Trial for IBD Therapeutic

    BRISBANE, Australia, June 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") today announces that the first participants have been successfully dosed in the Phase I Clinical Trial of MAP 315, in Microba’s Therapeutic Program in Inflammatory Bowel Disease (IBD). This milestone brings Microba’s drug candidate MAP 315 into clinical development as a potential new treatment option for the millions of people suffering from ulcerative colitis.